Biotech Values

[biomaven0]

Momenta's launch is not "at-risk."

I was replying to Mouton's question/comment about why companies can launch a generic at-risk and not generally be subject to an injunction. The standard for granting a TRO or preliminary injunction is similar in that situation and the current one.

It's hard to get one in an at-risk launch and it's even harder (in my judgment) for Sanofi to get one here.

Peter